Tag: Tyrosine kinase inhibitors

In the United States, approximately 20 million people have some form of age-related macular degeneration (AMD), and about 200,000 new cases of wet AMD are diagnosed annually [1.10.2]. While anti-VEGF therapy has been a revolutionary treatment, researchers are actively exploring alternatives to reduce treatment burden. So, what is the alternative to anti-VEGF?

According to a 2015 study, the use of lithium has been associated with up to a five-fold increase in the risk of developing hypothyroidism. This phenomenon, where specific prescription drugs trigger an underactive thyroid, answers the question, 'what medications cause low thyroid levels?'.

The human genome encodes 518 different protein kinases, many of which are targets for modern drugs [1.8.4]. If you've ever looked at the names of modern cancer medications and asked, **'Why do drug names end in nib?'**, the answer lies in a systematic naming convention that reveals the drug's mechanism of action.

Dozens of targeted therapy drugs have been approved in the field of oncology, with many identified as tyrosine kinase inhibitors (TKIs). These TKI medications, including many examples of what drugs have the suffix tinib, represent a targeted approach to treating cancer by inhibiting specific enzymes that drive tumor growth.

In clinical trials, diarrhea has been identified as a very common side effect of imatinib, affecting a significant portion of patients undergoing treatment for cancers like Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST). This gastrointestinal issue, often ranging from mild to moderate, is a recognized consequence of the drug's mechanism of action.

The development of imatinib, the first approved tyrosine kinase inhibitor, revolutionized the treatment landscape for chronic myeloid leukemia (CML), transforming a fatal disease into a manageable chronic condition for many patients. This groundbreaking innovation introduced the world to the power of a **tinib drug**, a targeted medication ending in the suffix “-tinib.”